Mutual Advisors LLC Lowers Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mutual Advisors LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 26.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,259 shares of the biopharmaceutical company’s stock after selling 4,390 shares during the period. Mutual Advisors LLC’s holdings in Gilead Sciences were worth $777,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Advisors Preferred LLC bought a new stake in Gilead Sciences in the 2nd quarter worth approximately $26,000. First Financial Corp IN grew its position in Gilead Sciences by 286.4% in the 3rd quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 401 shares during the period. Legacy Advisors LLC bought a new stake in Gilead Sciences in the 2nd quarter worth approximately $37,000. Venturi Wealth Management LLC bought a new stake in Gilead Sciences in the 3rd quarter worth approximately $40,000. Finally, Evolution Wealth Advisors LLC bought a new stake in Gilead Sciences in the 2nd quarter worth approximately $46,000. Institutional investors and hedge funds own 79.91% of the company’s stock.

A number of equities research analysts have commented on the stock. Oppenheimer cut their target price on shares of Gilead Sciences from $85.00 to $80.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Monday, July 15th. Citigroup set a $78.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, July 31st. Finally, Mizuho set a $81.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $79.27.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 4,000 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $64.52, for a total value of $258,080.00. Following the sale, the executive vice president now owns 23,921 shares in the company, valued at approximately $1,543,382.92. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 5,677 shares of the business’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $63.31, for a total transaction of $359,410.87. Following the completion of the sale, the executive vice president now owns 21,521 shares in the company, valued at approximately $1,362,494.51. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,193 shares of company stock worth $970,286. 0.20% of the stock is owned by corporate insiders.

Shares of GILD traded down $1.64 during trading hours on Thursday, reaching $63.77. 82,109 shares of the stock traded hands, compared to its average volume of 6,010,795. The company has a current ratio of 3.06, a quick ratio of 2.96 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $72.90. The company’s 50-day moving average price is $64.20 and its two-hundred day moving average price is $65.24. The company has a market cap of $82.59 billion, a P/E ratio of 10.46, a price-to-earnings-growth ratio of 3.46 and a beta of 1.09.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.01. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The company had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.61 billion. During the same quarter in the previous year, the company earned $1.84 EPS. Gilead Sciences’s revenue for the quarter was up .1% on a year-over-year basis. On average, research analysts forecast that Gilead Sciences, Inc. will post 6.66 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.95%. The ex-dividend date is Thursday, December 12th. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: Differences Between Momentum Investing and Long Term Investing

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.